Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for NVAX
5.92
+0.11 (1.89%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.73 - 5.97
52 week 3.34 - 6.95
Open 5.85
Vol / Avg. 1.21M/3.06M
Mkt cap 1.41B
P/E     -
Div/yield     -
EPS -0.30
Shares 238.48M
Beta 1.45
Inst. own 64%
Mar 9, 2015
Q4 2014 Novavax Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Dec 3, 2014
Novavax Inc at Piper Jaffray Healthcare Conference
Nov 20, 2014
Novavax Inc at Jefferies Global Healthcare Conference - London
Nov 5, 2014
Q3 2014 Novavax Inc Earnings Call
Nov 5, 2014
Q3 2014 Novavax Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -240.16% -248.54%
Operating margin -240.92% -250.70%
EBITD margin - -235.88%
Return on average assets -26.18% -30.81%
Return on average equity -29.12% -36.68%
Employees 213 -
CDP Score - -

Address

20 FIRSTFIELD ROAD
GAITHERSBURG, MD 20878
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

Officers and directors

James F. Young Ph.D. Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President, Treasurer
Age: 51
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. Senior Vice President - Research & Development
Age: 60
Bio & Compensation  - Reuters
Sven Andreasson Senior Vice President - Corporate Development
Age: 62
Bio & Compensation  - Reuters
Timothy J. Hahn Ph.D. Senior Vice President - Manufacturing and Process Development
Age: 50
Bio & Compensation  - Reuters
Cynthia N. Oliver Ph.D. Senior Vice President - Process Development Operations
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Russell P. Wilson J.D. Senior Vice President - Business Development
Age: 54
Bio & Compensation  - Reuters
Louis F. Fries Vice President, Chief Medical Officer
Bio & Compensation  - Reuters